介入超声治疗甲状腺切除术后声带功能障碍的初步探索性研究
回顾性分析21例甲状腺切除术后声嘶患者接受超声引导下得宝松与生理盐水混合液注射治疗,并与21例未治疗患者对照;治疗后1、2、3个月声带活动改善率均显著高于对照组,VHI与GRBAS评分显著改善,未观察到治疗相关不良反应。
要点
- 甲状腺切除术后声嘶患者行超声引导下得宝松注射,1、2、3个月声带活动改善率分别为28.6%、81.0%、90.5%,均高于未治疗组的0.0%、23.8%、33.3%。
- 治疗后VHI评分由72.6±21.2降至12.6±24.7,GRBAS评分由12.0降至0.0,均具统计学显著性。
- 2周内干预组声带活动改善时间19.8±5.8天,延迟干预组14.0±2.6天,前者恢复更慢;原文未观察到治疗相关不良反应。
核心结论
- 介入超声是甲状腺切除术后声嘶的安全有效治疗方法,可有效改善声带活动度并加速嗓音恢复。
研究设计与样本
- 回顾性研究,得宝松组21例(2023年8月1日至2024年1月31日在本院接受超声引导下得宝松与生理盐水混合液注射),对照组21例(同期未接受任何治疗),并比较2周内干预组与延迟干预组。
诊断标准与关键数值
- 得宝松组甲状腺切除术后1个月声带活动改善率28.6%,对照组0.0%,p<0.05。
- 得宝松组术后2个月声带活动改善率81.0%,对照组23.8%,p<0.05。
- 得宝松组术后3个月声带活动改善率90.5%,对照组33.3%,p<0.05。
- VHI评分治疗前后72.6±21.2 vs 12.6±24.7,p<0.001;GRBAS评分治疗前后12.0 vs 0.0,p<0.001。
- 2周内干预组声带活动改善时间19.8±5.8天 vs 延迟干预组14.0±2.6天,p<0.05。
临床应用与阅片要点
- 作者认为介入超声是甲状腺切除术后声嘶的安全有效治疗方法,可有效改善声带活动度并加速嗓音恢复;2周内干预组声带活动改善时间19.8±5.8天,延迟干预组14.0±2.6天,前者恢复更慢;原文未观察到治疗相关不良反应。
局限性
- 原文标题标明为初步探索性研究。
- 得宝松组平均声带活动改善时间与既往研究未治疗患者比较,而非与本研究对照组直接比较。
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To explore the efficacy of interventional ultrasound treatment for hoarseness caused by nondisconnected recurrent laryngeal nerve injury after thyroidectomy.
MATERIALS AND METHODS: In this retrospective study, we analysed the clinical data of 21 patients who underwent interventional ultrasound therapy (ultrasound-guided injection of a Diprospan and saline mixture) for postthyroidectomy hoarseness at our hospital between August 1, 2023, and January 31, 2024 (the Diprospan group) and randomly selected 21 patients who did not receive any treatment for postthyroidectomy hoarseness during the same period as the control group. The average vocal cord activity improvement time for the Diprospan group was calculated and compared with that of untreated patients from previous studies. Vocal cord activity improvement rates were assessed at 1, 2, and 3 mo after thyroidectomy, and changes in the voice handicap index (VHI) and the subjective listening perception scale (GRBAS) scores before and after treatment were evaluated. Additionally, the efficacy was compared between patients treated within 2 wk (timely intervention group, TI group) and those treated 2 wk after thyroidectomy (delayed intervention group, DI group) to explore the impact of treatment timing on outcomes.
RESULTS: In the Diprospan group, the average vocal cord activity improvement time was 44.6 ± 4.7 d for those treated within 2 wk after thyroidectomy and 17.7 ± 1.5 d for those treated 2 wk after thyroidectomy, both of which were significantly shorter than the 6 mo to 1 y reported in the literature. The improvement rates at 1, 2, and 3 mo after thyroidectomy were significantly greater in the Diprospan group than in the control group (0.0% vs. 28.6%, 23.8% vs. 81.0%, 33.3% vs. 90.5%, p < 0.05). The VHI score (72.6 ± 21.2 vs. 12.6 ± 24.7, p < 0.001) and GRBAS score (12.0 vs. 0.0, p < 0.001) significantly improved after treatment. Compared with the DI group, the TI group also showed faster voice recovery (19.8 ± 5.8 d vs. 14.0 ± 2.6 d, p < 0.05). No treatment-related adverse reactions were observed.
CONCLUSION: Interventional ultrasound is a safe and effective treatment for hoarseness after thyroidectomy, as it effectively improves vocal cord mobility and accelerates voice recovery.
引用
- Jiang Z, Zhu Y, Li B, et al. Effect of Interventional Ultrasound in the Treatment of Postthyroidectomy Vocal Cord Dysfunction: A Preliminary Exploratory Study. Ultrasound Med Biol. 2024. PMID: 39732573. doi:10.1016/j.ultrasmedbio.2024.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。